Detection and characterization of immunoconglutinins in patients with systemic lupus erythematosus (SLE): serial analysis in relation to disease course
暂无分享,去创建一个
B. Nilsson | K. Ekdahl | A. Sjöholm | G. Sturfelt | U. Nilsson | A. G. Sjöholm | Gunnar Sturfelt | U. R. Nilsson
[1] D. Sackett,et al. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. , 1992, Arthritis and rheumatism.
[2] G. Füst,et al. The role of C3 in the immune response. , 1991, Immunology today.
[3] J. Bonnetblanc,et al. The subclass distribution of IgG autoantibodies in cicatricial pemphigoid and epidermolysis bullosa acquisita. , 1991, The Journal of investigative dermatology.
[4] P. Limburg,et al. Predominance of IgGl and IgG4 subclasses of anti‐neutrophil cytoplasmic autoantibodies (ANCA) in patients with Wegener's granulomatosis and clinically related disorders , 1991, Clinical and experimental immunology.
[5] B. Nilsson,et al. Purification and characterization of IgG immunoconglutinins from patien with systemic lupus erythematosus: implications for a regulatory functiot , 1990, Clinical and experimental immunology.
[6] K. Sayama,et al. Subclass Characteristics of IgG Autoantibodies in Bullous Pemphigoid and Pemphigus , 1990, The Journal of dermatology.
[7] B. Nilsson,et al. Inhibition of factor I by diisopropylfluorophosphate. Evidence of conformational changes in factor I induced by C3b and additional studies on the specificity of factor I. , 1990, Journal of immunology.
[8] J. Nossent,et al. Low avidity antibodies to double stranded DNA in systemic lupus erythematosus: a longitudinal study of their clinical significance. , 1989, Annals of the rheumatic diseases.
[9] M. Brüggemann,et al. Human monoclonal IgG isotypes differ in complement activating function at the level of C4 as well as C1q , 1988, The Journal of experimental medicine.
[10] P. Wooley,et al. Assessment of the potential pathogenicity of type II collagen autoantibodies in patients with rheumatoid arthritis. Evidence of restricted IgG3 subclass expression and activation of complement C5 to C5a. , 1986, Arthritis and rheumatism.
[11] C. Durand,et al. A new enzyme-linked immunosorbent assay (ELISA) for measuring immunoconglutinins directed against the third component of human complement. Findings in systemic lupus erythematosus. , 1984, Journal of immunological methods.
[12] A. Sjöholm,et al. Complement components, complement activation, and acute phase response in systemic lupus erythematosus. , 1984, International archives of allergy and applied immunology.
[13] R. Maini,et al. Measurement of the complement C3 breakdown product C3d by rocket immunoelectrophoresis. , 1982, Journal of immunological methods.
[14] H. Gresham,et al. Large scale isolation of functionally active components of the human complement system. , 1981, The Journal of biological chemistry.
[15] M. Pepys,et al. Radioimmunoassay for immunoconglutinins. , 1980, Journal of immunological methods.
[16] T. Barkas,et al. Biological activities of complement. , 1978, Biochemical Society transactions.
[17] J. Bienenstock,et al. Immunoconglutinin in various rheumatic diseases and certain diseases suspected of an autoimmune pathogenesis. , 1967, Arthritis and rheumatism.
[18] C. Laurell,et al. Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies. , 1966, Analytical biochemistry.
[19] Orstavik Kh. Inhibitors to factor IX contain all IgG subclasses except IgG3. , 1990 .
[20] P. Lachmann. Conglutinin and immunoconglutinins. , 1967, Advances in immunology.